Relmada Therapeutics opened lower at $4.40, compared with its previous close of $4.43. In the last trading session, the stock traded between $4.14 and $4.47. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Relmada Therapeutics is now worth
$ 16.24
Resulting in a loss of
$ 83.76 (83.76%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.26 (-5.94%)
Day High
$4.47
Day Low
$4.14
Day Open
$4.40
Prev Close
$4.43
Volume
8,20,167
1W Return
-0.24%
1M Return
18.65%
3M Return
-6.63%
6M Return
-43.38%
1Y Return
26.66%
Fundamentals
Market Cap ($ Mn)
444
PE Ratio
-
PB Ratio
2.24
PEG Ratio
-
ROE
-168.89%
ROCE
-171.66%
EPS (TTM)
$-0.12
Investment Returns
1 Week
-0.24%
1 Month
18.65%
3 Months
-6.63%
6 Months
-43.38%
9 Months
4.17%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
16Jul
Relmada Therapeutics to announce Q2 2026 financial results
Relmada Therapeutics will announce its Q2 2026 financial results on August 6, 2026, via a conference call and webcast. The company will also discuss recent business progress, with a replay available on its website.
3mo ago
29Jun
Relmada Therapeutics joins Russell 2000 and 3000 Indexes
Relmada Therapeutics was added to the Russell 2000 and 3000 Indexes on June 26, 2026, enhancing its visibility among investors. CEO Sergio Traversa highlighted the company's robust NDV-01 data and strong financial position. The Russell 3000 tracks the largest 3,000 U.S. stocks, while the Russell 2000 measures small-cap performance.
4mo ago
18Jun
Relmada's cancer drug data drives Buy rating at HC Wainwright
HC Wainwright initiated coverage on Relmada Therapeutics Inc. with a Buy rating and a $12 price target, highlighting strong Phase 2 interim data for NDV-01 in bladder cancer. The analyst noted the drug's potential as a next-generation delivery platform with patent protection expected through 2047.
4mo ago
11Jun
Relmada Therapeutics appoints Michael Quirk as Senior Advisor for sepranolone program
Relmada Therapeutics has appointed Michael Quirk, PhD, as Senior Advisor for its sepranolone program targeting Prader-Willi Syndrome and other CNS indications. Quirk brings over 20 years of experience, including his tenure as Chief Scientific Officer at Sage Therapeutics. His expertise will support the advancement of sepranolone, a GABA-A receptor modulator.
